HC Wainwright Reaffirms “Buy” Rating for Tyra Biosciences (NASDAQ:TYRA)

HC Wainwright reaffirmed their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research report released on Monday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock.

TYRA has been the topic of several other reports. Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. UBS Group began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target on the stock. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, Oppenheimer raised their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Stock Up 5.0 %

NASDAQ:TYRA opened at $16.73 on Monday. The stock has a market capitalization of $846.59 million, a PE ratio of -10.39 and a beta of 1.04. Tyra Biosciences has a 52 week low of $12.17 and a 52 week high of $29.60. The stock’s 50-day moving average price is $15.40 and its 200-day moving average price is $19.20.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Sell-side analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Todd Harris sold 19,084 shares of the company’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $27.90, for a total value of $532,443.60. Following the completion of the sale, the chief executive officer now owns 1,355,927 shares of the company’s stock, valued at approximately $37,830,363.30. This represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Nina S. Kjellson sold 27,493 shares of Tyra Biosciences stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $16.56, for a total transaction of $455,284.08. Following the transaction, the director now directly owns 458,506 shares in the company, valued at $7,592,859.36. This trade represents a 5.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,731 shares of company stock worth $1,185,162. 15.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. HighVista Strategies LLC acquired a new stake in Tyra Biosciences during the second quarter worth $257,000. Franklin Resources Inc. purchased a new position in shares of Tyra Biosciences during the 3rd quarter worth $278,000. Valence8 US LP purchased a new position in shares of Tyra Biosciences during the 3rd quarter worth $310,000. SG Americas Securities LLC acquired a new stake in shares of Tyra Biosciences during the 3rd quarter worth about $311,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Tyra Biosciences in the 3rd quarter valued at about $333,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.